Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Vicor

4 Stocks That Crushed Analyst Estimates by More Than Double

Hims & Hers, Alcoa, Vicor, and Stride crushed earnings with massive EPS beats. See what’s driving their growth and future potential.

Vicor Joins Elite Club Of Stocks With RS Ratings Over 90

Vicor Joins Elite Club Of Stocks With RS Ratings Over 90

Vicor shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

Vicor Stock Earns Relative Strength Rating Upgrade After Earnings

Vicor Stock Earns Relative Strength Rating Upgrade After Earnings

A Relative Strength Rating upgrade for Vicor shows improving technical performance.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Vicor Stock Shows Rising Composite Ratings With Earnings Release

On Thursday, Vicor got an upgrade for its IBD SmartSelect Composite Rating from 91 to 97.

Investors Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022

A Preview Of Vicor's Earnings

Vicor (NASDAQ:VICR) is set to give its latest quarterly earnings report on Thursday, 2022-04-21. Here's what investors need to know before the announcement. Analysts estimate that Vicor will report an earnings per share (EPS) of $0.27.

Here's How Much $100 Invested In Vicor 15 Years Ago Would Be Worth Today

Vicor (NASDAQ:VICR) has outperformed the market over the past 15 years by 5.26% on an annualized basis producing an average annual return of 13.2%. Currently, Vicor has a market capitalization of $2.83 billion.

inkl

Read news from The Economist, FT, and more,
with one subscription

Vicor: Q4 Earnings Insights

Vicor: Q4 Earnings Insights

Vicor (NASDAQ:VICR) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Vicor missed estimated earnings by 55.56%, reporting an EPS of $0.2 versus an estimate of $0.45.

1

Organisations

the White House

Abbott Laboratories

Regeneron Pharmaceuticals

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play